Either a
non-nucleoside reverse transcriptase inhibitor (NNRTI; ie, efavirenz, rilpivirine),
a protease inhibitor (ie, atazanavir or darunavir, each boosted by ritonavir), or an INSTI
(ie, RAL, DTG, or EVG boosted by cobicistat) may complete the regimen